Skip to Main Content

A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy

Conditions

Lung

Phase II

What is the purpose of this trial?

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Find out more about who can participate in this trial
  • Trial with
    Astra Zeneca
  • Start Date
    02/24/2020
  • End Date
    08/31/2022
Trial Image

For more information about this study, contact:

Kira Pavlik

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sub-Investigators

  • Last Updated
    02/26/2020
  • Study HIC
    #2000025651

Contact Information

For more information about this study, including how to volunteer, contact Kira Pavlik

Volunteer Now